X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and reverse immune suppression, which is fundamental to treating cancer and certain rare, genetic primary immunodeficiency diseases. Our oral, small molecule drug candidates inhibit the binding of chemokine CXCL12 to C-X-C receptor type 4 (CXCR4), a receptor-ligand pair that plays an essential role in normal immune surveillance. We are committed to advancing the fields of cancer immunotherapy and genetic immune disorders through innovation and investment in our proprietary clinical and preclinical pipeline.
X4’s most advanced product candidate, X4P-001-RD, is in a Phase 2/3 study in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease. X4P-001-IO is currently under investigation in multiple Phase 1/2 studies in refractory clear cell renal cell carcinoma (ccRCC) and melanoma.
Our third program, X4P-002, is in preclinical development and designed specifically for the treatment of brain cancers, including glioblastoma multiforme (GBM).
X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA.